TY - JOUR

T1 - PsyCog

T2 - A computerised mini battery for assessing cognition in psychosis

AU - Gifford, George

AU - Cullen, Alexis E.

AU - Vieira, Sandra

AU - Searle, Anja

AU - McCutcheon, Robert A.

AU - Modinos, Gemma

AU - Stone, William S.

AU - Hird, Emily

AU - Barnett, Jennifer

AU - van Hell, Hendrika H.

AU - Catalan, Ana

AU - Millgate, Edward

AU - Taptiklis, Nick

AU - Cormack, Francesca

AU - Slot, Margot E.

AU - Dazzan, Paola

AU - Maat, Arija

AU - de Haan, Lieuwe

AU - Facorro, Benedicto Crespo

AU - Glenthøj, Birte

AU - Lawrie, Stephen M.

AU - McDonald, Colm

AU - Gruber, Oliver

AU - van Amelsvoort, Thérèse

AU - Arango, Celso

AU - Kircher, Tilo

AU - Nelson, Barnaby

AU - Galderisi, Silvana

AU - Bressan, Rodrigo A.

AU - Kwon, Jun Soo

AU - Weiser, Mark

AU - Mizrahi, Romina

AU - Sachs, Gabriele

AU - Kirschner, Matthias

AU - Reichenberg, Abraham

AU - Kahn, René

AU - McGuire, Philip

AU - PSYSCAN Consortium

N1 - Publisher Copyright: © 2024

PY - 2024

Y1 - 2024

N2 - Despite the functional impact of cognitive deficit in people with psychosis, objective cognitive assessment is not typically part of routine clinical care. This is partly due to the length of traditional assessments and the need for a highly trained administrator. Brief, automated computerised assessments could help to address this issue. We present data from an evaluation of PsyCog, a computerised, non-verbal, mini battery of cognitive tests. Healthy Control (HC) (N = 135), Clinical High Risk (CHR) (N = 233), and First Episode Psychosis (FEP) (N = 301) participants from a multi-centre prospective study were assessed at baseline, 6 months, and 12 months. PsyCog was used to assess cognitive performance at baseline and at up to two follow-up timepoints. Mean total testing time was 35.95 min (SD = 2.87). Relative to HCs, effect sizes of performance impairments were medium to large in FEP patients (composite score G = 1.21, subtest range = 0.52–0.88) and small to medium in CHR patients (composite score G = 0.59, subtest range = 0.18–0.49). Site effects were minimal, and test-retest reliability of the PsyCog composite was good (ICC = 0.82–0.89), though some practice effects and differences in data completion between groups were found. The present implementation of PsyCog shows it to be a useful tool for assessing cognitive function in people with psychosis. Computerised cognitive assessments have the potential to facilitate the evaluation of cognition in psychosis in both research and in clinical care, though caution should still be taken in terms of implementation and study design.

AB - Despite the functional impact of cognitive deficit in people with psychosis, objective cognitive assessment is not typically part of routine clinical care. This is partly due to the length of traditional assessments and the need for a highly trained administrator. Brief, automated computerised assessments could help to address this issue. We present data from an evaluation of PsyCog, a computerised, non-verbal, mini battery of cognitive tests. Healthy Control (HC) (N = 135), Clinical High Risk (CHR) (N = 233), and First Episode Psychosis (FEP) (N = 301) participants from a multi-centre prospective study were assessed at baseline, 6 months, and 12 months. PsyCog was used to assess cognitive performance at baseline and at up to two follow-up timepoints. Mean total testing time was 35.95 min (SD = 2.87). Relative to HCs, effect sizes of performance impairments were medium to large in FEP patients (composite score G = 1.21, subtest range = 0.52–0.88) and small to medium in CHR patients (composite score G = 0.59, subtest range = 0.18–0.49). Site effects were minimal, and test-retest reliability of the PsyCog composite was good (ICC = 0.82–0.89), though some practice effects and differences in data completion between groups were found. The present implementation of PsyCog shows it to be a useful tool for assessing cognitive function in people with psychosis. Computerised cognitive assessments have the potential to facilitate the evaluation of cognition in psychosis in both research and in clinical care, though caution should still be taken in terms of implementation and study design.

KW - Clinical high risk for psychosis

KW - Cognition

KW - First episode psychosis

KW - Psychosis

U2 - 10.1016/j.scog.2024.100310

DO - 10.1016/j.scog.2024.100310

M3 - Journal article

C2 - 38572271

AN - SCOPUS:85188990680

VL - 37

JO - Schizophrenia Research: Cognition

JF - Schizophrenia Research: Cognition

SN - 2215-0013

M1 - 100310

ER -